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As evidence mounts that antiretrovirals (ARVs)  
are effective for HIV prevention, policymakers  
and program managers will need to determine 
whether and how best to introduce specific  
products into health care systems. Determining  
the most appropriate users within a particular 
country will depend on the overall context, the  
nature of the HIV epidemic within the country, 
and the opportunities available to reach and serve 
HIV-negative women with ARV-based prevention 
products and services. 
This toolkit was developed by the Population  
Council for use by governments, organizations,  
and donors that are in a position to support or  
add new HIV-prevention products into programs. 
The toolkit was designed to help identify strategic 
opportunities for providing ARV-based products  
to women. The most effective mix of program  
entry points and delivery channels will vary from 
country to country. Similarly, the particular role a 
given product will play in a country will depend on  


























Introducing Antiretroviral (ARV)-Based Prevention 
Products for Women assists users in planning 
for the introduction of new HIV-prevention prod-
ucts (and accompanying services) in a manner 
that supports high-quality, integrated services. 
It guides policymakers and program managers 
through a systematic process of assessing the role 
and potential impact of a new product into their  
programs while considering the feasibility of  
introducing it in specific settings. 
This toolkit focuses on facility-based services; 
provision of ARV-containing products will likely 
be prescription-only at first and require capacity 
for HIV testing and monitoring. It guides users 
through a series of considerations to identify 
potential barriers and assets within the service 
setting, which should be considered in program 
design and planning. This process will result in a 
programmatic action plan for effective product 
introduction in a manner that supports individuals’ 
rights and promotes quality services.
nOTE:	This document is not designed as a  
detailed assessment tool. Numerous assessment 
guides and programming tools have been devel-
oped to design HIV/AIDS programs and services 
and to support integration of HIV/AIDS services 
into existing programs. (See Appendix 1 for a list of 
selected program and policy tools.) Most of these 
tools are geared toward large-scale facility assess-
ment and, therefore, require more time and re-
sources to implement than the process proposed 
here. Should it be required, these more in-depth 
assessment tools can be used to follow up and 
complement the action planning resulting from the 
use of this toolkit.
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mODUlE	1:	lAnDScAPE	AnAlySIS 
An analysis of the overall context of the HIV 
epidemic, along with a policy and HIV program 
scan, is an important first step. This analysis 
consists primarily of a desk review of available 
literature and data, supplemented as needed 
with input from experts familiar with the HIV 
epidemic and the specific country context. It 
will serve as a starting point and foundation 




Another key component involves conducting 
in-depth interviews (IDIs) with a select group 
of key opinion leaders (KOLS) who will be 
involved in or influence strategic decisions 
about the introduction of new ARV-based 
prevention products. Such KOLs can be iden-
tified from the “Potential Key Informants and 
Organizations” box (see page 4). IDIs should 
be conducted by a senior leader who is knowl-
edgeable about both HIV prevention and the 
country’s policy environment. Results will point 
to the strategic role a given product could play 
within a country’s HIV-prevention program and 
help determine a plan for introduction.
mODUlE	3:	PrOGrAm		
PlAnnInG	GUIDE	
After gathering input from KOLs, a  
facilitated workshop should be convened  
that includes policymakers, service providers, 
and program managers who are responsible 
for implementing HIV-prevention programs. 
Module 3 is designed to stimulate discussion 
among these invited groups.
APPEnDIXES	
	
Appendix	1 contains key guidelines and 
reference materials.
Appendix	2 provides a detailed sample 
workshop agenda.
 
Appendix	3 includes a checklist that will  
assess the readiness of service-delivery 

















A small, in-country team will be needed to manage the  
process. The team should include individuals with the  
following attributes:
•	 An appropriate mix of skills and a professional  
reputation to engage key decisionmakers and  
program leaders, and to ensure follow-up;
•	 In-depth knowledge of the country’s health system and 
its HIV-prevention program(s);
•	 Access to relevant professional networks; 

















Completing this process will equip the team with the 
elements needed to develop an introduction plan that 
defines:
•	 The strategic rationale for introducing a specific 
new product;
•	 Target populations to be served;
•	 Potential entry points and service settings for offer-
ing the product;























The landscape analysis consists primarily 
of a desk review, supplemented as needed 
and as possible with expert opinion and 
interviews with key informants. The analysis 
and synthesis will provide an overview of 
the nature and shape of the HIV epidemic in 
the country as well as a general overview of 
the policy environment and structure of the 
country’s health system.
The desk review relies primarily on existing 
datasets and publicly available information 
from credible and referenced sources (for 
example, Demographic and Health Surveys, 
UNAIDS HIV country profiles, country-specific 
plans and updates, if relevant). See Appendix 
1 (Key Guidelines and Reference Materials) 
for additional sources. The information should 
be presented in brief narrative and tabular 
form, with sources and citations provided. 
The output should include a summary with 
citations, data tables, appendixes of key 







1  Describe the country’s HIV epidemic. Use:
•	 National prevalence/incidence (stratified by age, 
gender, state/province/district)
•	 Trends in prevalence/incidence (stratified by age 
and gender)
•	 Populations with highest prevalence/incidence
•	 Coverage of antiretroviral therapy
•	 Important risk factors for women
•	 Age at first sex
•	 Age at marriage
•	 Concurrent sexual partnership patterns
•	 Intimate partner violence
•	 Most-at-risk populations (MARPs; defined  
in country context)
2  Describe results of Modes of Transmission 
Studies (MTS), if available.
3  Describe current contraceptive use patterns.
•	 Contraceptive prevalence (by age and region)
•	 Method mix; most commonly used method(s)  
(by age and region)
		POlIcy	EnVIrOnmEnT		
4  Describe the country’s current HIV policies.
•	 Which HIV-prevention approaches, including 
technologies (e.g., reducing number of partners, 
abstinence, oral pre-exposure prophylaxis [PrEP], 
voluntary medical male circumcision [VMMC]) are 
included in relevant policies? Which approaches are 
emphasized in which policies and for which user 
groups? 
•	 Describe service guidelines and protocols (and 
include in an accompanying Appendix, if available) 
specifically geared toward:
 – HIV-prevention programs
 – HIV-treatment programs
 – HIV and family planning/reproductive health 
integration
5  Is there documentation of any experiences 
regarding technology introduction in the country 
that can help inform the introduction of ARV-
based prevention for women? 
•	 regarding male or female condoms, reproductive 
health products, or antiretroviral therapy [ART],  
for example
 If yes, summarize key lessons from these 
experiences.
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6  Which policies, regulatory authorities, and 
agencies are involved in the approval and 
introduction of new HIV or reproductive health 
products?
7  Describe current policies, laws, and service-
delivery guidelines regarding the initiation, 
dispensing, and resupply of ARV-containing 
products. 
8  List any restrictions on HIV or SRH services.
 Are they based on: 
•	 Age
•	 Marital status
•	 Laws affecting key groups (sex workers,  
injecting drug users, men who have sex with  
men, etc.)
9  List any antidiscrimination laws protecting 
people living with HIV.
10  What is the breakdown of funding for HIV-treatment 
and prevention programs in the country?
•	 Note the approximate proportion of funding for  
HIV treatment and prevention that comes from 
different sources (e.g., national, provincial 
government, donor organizations, private sector, 
faith-based organizations, communication 
resources, individual/family out-of-pocket).
•	 Note the roles that public/private partnerships and/
or social marketing play.
•	 Note the proportion of HIV expenditures by 
commodities and programming for treatment and 
for prevention, if available.
11  Provide recent statistics (national, provincial, 
district) on use of these services, if available.
•	 HIV-treatment services
•	 HIV-prevention services (medical male circumci-
sion, prevention of mother-to-child transmission, 
postnatal care, post-exposure prophylaxis)
•	 Antenatal care




•	 Other relevant services
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12  Which sector—public, nongovernmental 
organization (NGO), or private—generally 
takes the lead on new health innovations and 
approaches?
		STrATEGIc	OPPOrTUnITIES		
13  Based on the available information and analysis, 
what are the main strategic opportunities for 
introducing ARV-based prevention for women? 
What are the main challenges? 
14  Are there any national initiatives that are ongoing 
or to be launched that may have a bearing on the 
introduction and financing of new products (e.g., 
National Health Insurance schemes, voucher 
systems, re-engineering of primary health care)? 
15  List other key insights or suggestions for 
research, policy, or programming to initiate ARV-








By exploring views and eliciting expert  
opinions, this module identifies key questions 
and issues that must be considered and ad-
dressed to inform decisions about introduc-
ing new products in the context of a country’s 
specific HIV epidemic, health system, and 
political and economic environment. 
Module 2 is structured as a questionnaire 
intended to guide individual in-depth  
interviews (IDIs) with carefully selected  
key opinion leaders and decisionmakers.  
The IDIs are conducted by a senior leader 
working in the HIV field. As such, it assumes 
a fairly high level of knowledge and aware-
ness of critical issues in HIV prevention 
and of the policymaking environment in 
the country. The guide considers scientific, 
political, and economic factors that drive 

















1  What scientific evidence would be needed  
to make a decision to introduce 
      [insert specific product]      in the country?  
[Probe, as needed:]
•	 Safety data
 – In the general population
 – In pregnant women
 – During breastfeeding
 – In adolescents
 – Impact on current and future fertility
•	 Effectiveness/level of efficacy (how well it works)
•	 Acceptability (and adherence)
•	 Potential resistance
2  How should the data be made available to 
decisionmakers (e.g., results of randomized 
controlled trials, journal articles, briefings)?  
What source of data would support the 
decisionmaking process? 
	TArGET	POPUlATIOnS		
The introduction of a new HIV-prevention product can in-
crease options for individuals to reduce their risk of infection 
and holds the potential for a broader public health impact. 
3  In your view, who will benefit most from using  




•	 Married women (Married women whose husbands 
work away from home)
•	 Sex workers
•	 Women who have infrequent but risky sex (e.g., 
exchange sex for money, food, shelter)
•	 Women who have multiple partners
•	 Women whose partners have multiple partners
4  Where do you see     [insert specific product]    fitting into 
the country’s HIV-prevention program vis-à-vis 
existing strategies?
(e.g., HIV counseling and testing, voluntary medical 
male circumcision (VMMC), oral PrEP, condom  
promotion, behavior-change communications)?
5  How would you prioritize      [insert specific product]       




6  What are the potential opportunities for 
delivering       [insert specific product]     ? Through which 
sectors and in which programs or services could 
this occur?   [Probe, as needed:]
•	 Public vs. NGO vs. private sector




•	 Type of program
 – ARV treatment
 – HIV testing and counseling
 – Voluntary medical male circumcision
 – Sexual and reproductive health
 – Antenatal care
 – Family planning
 – Well-baby
 – Other
7  If      [insert specific product]       was introduced in  
the country, what would be the implications  
for existing programs, services, and health 




•	 Staff deployment, task-shifting
8  Are there lessons (positive and negative)  
from the introduction of other technologies  
or prevention strategies that could inform plans 
for introducing     [insert specific product]      ?
	POlIcy	cOnSIDErATIOnS	
9  What do you see as the potential benefits and 
risks from introducing     [insert specific product]     ?   
[Probe, as needed:]
•	 Expanded options for prevention
•	 Equity
•	 Reactions from various constituencies—religious, 
community, advocacy groups
10  Who are the key players (organizations) that 
must be engaged in the decision about whether 
to introduce     [insert specific product]     ?    
[Probe, as needed:]
•	 Regulatory bodies (local and international) 
•	 Guidelines from normative agencies (WHO, etc.)
•	 Others
11  Are there champions for ARV-based prevention 
or HIV prevention for women in the country who 
could help advocate for       [insert specific product]     ?
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	EcOnOmIcS,	cOST,	AnD	fInAncInG	
Cost considerations, including manufacturing, often factor 
heavily in decisions about whether, how, and at what scale new 
health products should be produced and introduced. Many of 
these are influenced nationally and globally.
12  How would the decision be made whether to invest 
in introducing       [insert specific product]      ?
13  What would you or other decisionmakers need to 
know to make the investment case for       [insert specific 
product]      in order to allocate a budget for product 
procurement and introduction?
14  How do you think this product could be financed in 
the short term? The long term? 
15  How could supplying       [insert specific product]      to those 
who need it be sustained over the long term?
16  From your experience, can you comment on key 




•	 Pharmaco-vigillance/surveillance  
	DEcISIOnmAkInG		
17  If you were asked to make a decision today about 
whether to introduce       [insert specific product]     , what 
would you do? Why?
18  From your position and the role that you/your 
agency plays, what other information/data would 
you need to make a decision about introducing  
      [insert specific product]      ?








The module provides key questions that 
can be addressed through facilitated group 
discussions in a workshop format (a sample 
agenda is provided in Appendix 2). This 
module leads participants through a series 
of service-design considerations that need 
to be addressed in program planning. The 
outcome of this process is a plan for product 








1  How are new HIV-prevention methods 
incorporated into national HIV policies and 
strategic plans?
2  How are priorities set for HIV prevention and 
treatment programs, and at what level of the 
health system (national, provincial, or district)?
3  Which HIV-prevention approaches are 
emphasized in current plans? Are different 




4  In your view, what populations would benefit 





•	 Women who have infrequent but risky sex (e.g., 
exchange sex for money, food, shelter)
•	 Women who have multiple partners
•	 Women whose partners have multiple partners
5  For each group that would benefit, where and 
how would they best be reached?
	mESSAGInG	AnD	DEmAnD	crEATIOn		
6  Which organization is charged with developing 
and/or maintaining messages for HIV prevention 
generally? For ARV-based prevention for women 
in particular?
7  Describe key campaigns that are focused 
on HIV prevention for women. How were 
they developed? How would new ARV-based 
prevention products or services for women be 
best incorporated into these campaigns?
8  Which channels do these campaigns use? 
Which do you think are most effective?
•	 Mass media
•	 Peer education
•	 Clinic-based information, education, 
communication
•	 Community education
•	 Mobile and digital media
9  Do you have ideas about how best to create 
demand for this new product?
10  What specific lessons can be applied from other 
technology-introduction efforts?  
11  What do you anticipate will be the key barriers 
for women who wish to use the product?
12  How can existing programs be capitalized upon 
to support introduction? 
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	SErVIcE	PrOVISIOn	
13  How well do you think HIV prevention is currently 




•	 Primary health 
14  ARV-based prevention products will require 
counseling, HIV testing, and monitoring. Which 
service settings might afford good opportunities for 
delivering this product?  [Probe, as needed:]
•	 HIV counseling and testing (HCT)?
•	 Family planning?
•	 School-based programs (adolescents)?
•	 Antenatal care?
•	 Services for sero-discordant couples?
•	 Sexually transmitted infection services?
•	 Primary health?
15  In the settings that have been identified as 
favorable for integrating ARV-based prevention for 
women, are facilities generally adequate? 
 Consider whether:
•	 Essential supplies/commodities (including HIV tests) 
are routinely available
•	 Facilities have patient-education materials on ARV-
based prevention to support community- and clinic-
based education
•	 Facilities are able to handle specific commodity 
requirements (storage space, shelf life, temperature, 
stock control, security, expiration)
16  Is staffing generally adequate? 
•	 Given resource constraints, how might services be 
provided and by whom?
•	 Can you envision assigning clinic staff to the specific 
task of providing clients with, and counseling them on, 
this product? 
•	 Would there be opportunities for training different 
cadres of staff in ARV-based prevention and 
counseling?
17  How do existing human resource training strategies 
incorporate: 
•	 HIV-prevention approaches?
•	 Family planning/reproductive health?
•	 HIV treatment, counseling, and care?
•	 Are there specific training materials or curriculums 
that could be adapted to include ARV-based 
prevention for women? 
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18  What staffing will be needed to support the 
introduction of a new ARV-based prevention 
product for women? 
•	 Which cadres of health personnel (e.g., nurses, 
physicians, counselors, health officers)?
•	 At which levels of the health system (district,  
province, community)?
19  What do you foresee as the key challenges 
providers may face in offering ARV-based 
prevention products for women?
	cOmmODITIES/SUPPly	cHAIn/lOGISTIcS	
20  Is there an effective commodity-security  
program (for HIV and/or reproductive health 
commodities) that currently exists and could  
be used for new HIV-prevention products? If 
not, what areas of the supply chain require 
strengthening?
21  What commodities are currently available for HIV 
prevention (e.g., HIV test kits, male condoms, 
female condoms)? And:
•	 Who provides them?
•	 Who pays for them (e.g., national government, donor 
agencies)?
•	 What client fees or cost-sharing is levied on these 
commodities?
•	 How would a new product be added to the HIV 
commodities-procurement list?
•	 What do you think will be the challenges regarding 
procurement and supply of ARV-based products? 
	ImPlIcATIOnS/SPEcIAl	cHAllEnGES	
22  Do you have any concerns related to an ARV-based 
prevention product that uses the same active drug 
used in treatment regimens?
•	 Real or perceived tension between resources for 
treatment and prevention?
•	 Potential resistance?
23  Are there systems for post-marketing surveillance 
and pharmaco-vigilance that can be used to track 
HIV resistance, adverse events, or side effects 
related to ARV-based prevention products? 
Appendixes   
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Appendix 1  
Key Guidelines and Reference Materials
The key guidelines found in the toolkits and manuals listed below have been produced by collaborating agencies and other major institutions known 
for their work within the fields of HIV/AIDS and sexual/reproductive health.
Bristol-Myers Squibb Foundation, Southern 
Africa HIV Clinicians Society and International 
Training and Education Center on HIV (I-TECH). 
2007. “Secure the future manual: Seven steps 
to involve the community in HIV/AIDS treat-
ment support programmes, first edition.”  
New York: Bristol-Myers Squibb Foundation. 
http://www.securethefuture.com/our_ 
experience/STF_manual_first_edition.pdf
Farrell, Betty L. 2007. “Family planning– 
integrated HIV services: A framework for 
integrating family planning and antiretroviral 





FHI360. 2008. “Increasing access to contracep-
tion for clients with HIV: A toolkit.” Research 
Triangle Park, NC: FHI360.  http://www.fhi360.
org/training/en/modules/FPHIV_toolkit/ 
interface.pdf
Futures Group. 2000. “The AIDS impact model  
(AIM) approach.” Washington, DC: Futures 
Group/POLICY Project. http://www. 
policyproject.com/pubs/bookgreen.pdf
International AIDS Vaccine Initiative (IAVI). 2009. 
“Integrating gender issues into AIDS vaccine 
clinical research: A training manual for Sub- 





International HIV/AIDS Alliance. 2010. “Integra-
tion of HIV and sexual and reproductive health 
and rights: Good practice guide.” Brighton, UK.  
http://www.aidsalliance.org/includes/ 
Publication/SRHGPG2.pdf
John Snow, Inc. (JSI). 2009. “Quantification of 
health commodities: A guide to forecasting 
and supply planning for procurement.” Arling-
ton, VA: JSI–USAID DELIVER Project, Task 
Order 1. http://sc4ccm.jsi.com/Docs/ 
QuantHealthCommunity.pdf
Joint United Nations Programme on HIV/AIDS 
(UNAIDS). 2011. “Joint strategic action frame-
work to accelerate the scale-up of voluntary 
medical male circumcision for HIV prevention 





K4Health. 2014. “Microbicides toolkit.” Research 
Triangle Park, NC: FHI360. http://www.
k4health.org/toolkits/microbicides
MacQueen, Kathleen and Mike May. 2008.  
“Partnering for care in HIV prevention trials:  




Patel, A. et al. 2010. “Pediatric HIV treatment 
toolkit: A practical guide to the implementation 
of the 2009 World Health Organization pediat-
ric HIV treatment recommendations.” Arling-




Raney, Laura et al. 2008. “Balanced counseling 
strategy plus user’s guide,” in The Balanced 
Counseling Strategy Plus: A Toolkit for Family 
Planning Service Providers Working in High 





Robinson, Elizabeth T. et al. 2010. “Communica-
tions handbook for clinical trials: Strategies, 
tips, and tools to manage controversy, convey 
your message, and disseminate results.” 
Research Triangle Park, NC: FHI360/ 
Contraceptive and Reproductive Health  





Ross, John and Ellen Smith. 2010. “The family  
planning effort index: 1999, 2004, and 
2009.” Washington, DC: Futures Group/




Sanders, Rachel, Karen Hardee, and Carol  
Shepherd.  2007. “Implementing integrated 
family planning and HIV/AIDS policies and 
programs: Tools and resources.” Washing-




USAID, Center for Accelerating Innovation and 
Impact (CII). 2015. “Idea to impact. A guide  
to introduction and scale of global health  
innovations.”  Washington, DC: CII. http:// 
www.usaid.gov/cii/guide-introduction- 
and-scale 
World Health Organization (WHO). 2004. 
“A guide to rapid assessment of human 
resources for health.” Geneva: WHO.  
http://www.who.int/hrh/tools/en/ 
Rapid_Assessment_guide.pdf
———. 2009. “Integrating gender into HIV/
AIDS programmes in the health sector: 
Tool to improve responsiveness to women’s 
needs.” Geneva: WHO. http://www.who.int/
gender/documents/gender_hiv_ 
guidelines_en.pdf
WHO, International HIV/AIDS Alliance, and 
PharmAccess International. 2003. “A public 
health approach for scaling up antiretroviral 
treatment: A toolkit for programme manag-
ers.” Geneva: WHO. http://www.who.int/hiv/
pub/prev_care/arvtoolkit_en.pdf
WHO, United Nations Population Fund, 
UNAIDS, and International Planned Par-
enthood Foundation. 2005. “Linking sexual 
and reproductive health and HIV/AIDS: An 




Listed in the table below are program and policy tools that were reviewed prior to and informed the development of this toolkit.







2008 Can be used by decisionmakers to assess the fea-
sibility of linking services, identify programmatic 
or structural barriers to integration, pilot-test ap-
proaches to integrating services, evaluate effects 
of linked or integrated services, and assess/evalu-
ate costs of integrated services models.
Multiple country settings, 
including Bangladesh, 
Bolivia, Dominican 
Republic, Egypt, Ghana, 
Guatemala, India, Kenya, 







EngenderHealth 2008 Provides materials for identifying and solving on-
site problems that compromise the quality of HIV 
care and treatment services. The tools address: 
informed consent, confidentiality, clinical manage-
ment of HIV, provision of ART, positive prevention, 
and integration of SRH and HIV services.
Field-tested in Uganda. 








Health Policy  
Initiative—  
Futures/UNAIDS
2009 This tool was developed to enable decisionmakers 
to understand the potential cost and impact of 
various options for scaling up male circumcision 

















Designed for use by family planning providers 
to help clients make informed choices about 
contraceptive methods and to give clients the 
information and help they need to use their cho-
sen method successfully. Adaptation guidelines 
provided for specific methods and contexts.
Indonesia, Mexico, 
Nicaragua, South Africa, 





Measure DHS Multiple 
years
Offers a comprehensive overview of a country’s 
health-care services and its capacity to provide 
quality care. SPA surveys examine the supply side 
of health care, showing the strengths and weak-
nesses of a country’s public and private services. 
It focuses on five key services: child health, mater-
nity and newborn care, family planning, STIs and 










2008 Provides information on types of service, status 
and functionality of infrastructure, equipment, 
and quality of care. It facilitates local (e.g., proj-
ect- or district-level) and low-cost monitoring of 
availability and quality of facility-based reproduc-
tive and child-health services at government and 
private facilities, including private clinics.









FHI360 2007 Tool is designed to help governments and 
organizations determine availability/quality 
of essential elements of HIV services, gather 
necessary data about these services, and plan for 
program implementation.
Cambodia, Ethiopia, Kenya, 








2010 Developed to assist governments and donors with 
the development of HIV/AIDS policies and imple-
mentation plans.
Cote d’Ivoire, Guyana, 
Haiti, Kenya, Nigeria, Sierra 














2004 A review was conducted of instruments that were 
used in this study to explore and identify issues 









1997 Designed to measure the overall status of the 
policy environment for SRH, FP, adolescent RH, 
HIV/AIDS, safe motherhood, and PAC in a particular 
country, evaluating changes in the policy environ-
ment over time and identifying those areas most 
in need of improvement. 






Pathfinder 2003 Enables those involved in health management 
to collect detailed information on the range and 
quality of integrated services available at a given 
facility and thus to facilitate the design of more 








IPFP, UNFP, WHO, 
UNAIDS, et al. 
2009 Can be used to assess links between HIV and SRH 
at policy, program, and facility levels, and ulti-
mately contribute to the development of country- 
specific action plans to forge and strengthen 
linkages.
19 countries in Africa, Asia, 





EngenderHealth 2011 Designed to help determine strengths and 
weaknesses in FP programs by identifying gaps 
that require further investment or more in-depth 
assessment prior to (re)designing interventions.
Burkina Faso, Mali, Nigeria, 







John Snow, Inc. 
(JSI)
2007 This tool was designed to provide sites and pro-
grams with a set of criteria to assess a site’s read-
iness to implement ART or the current capacity 
and needs of an existing program, and to identify 
key areas that need strengthening.
Field tested in Zimbabwe. 
Used in multiple country 
settings. 
	 23




(0.5 hour)  Welcome,	participant	introduction,	purpose	of	meeting
SESSIOn	2	 Purpose: Ensure that all participants share a common understanding
(1.5 hours)  about tenofovir gel as well as technical and contextual factors related 
to its introduction.  
 Setting	the	stage (plenary presentations by technical experts):  
•	 Technical update on tenofovir gel (expert slides will be provided, 
detailing mechanism of action, status of clinical trials and 
research, and key issues for service delivery)
•	 Summary of results of landscape analysis (Module 1)
•	 Summary of results from interviews with key opinion leaders and 
decisionmakers (Module 2)
    –break– 
SESSIOn	3	 Purpose: Participants consider the information from the previous
(1.5 hours) session to identify strategic roles that tenofovir gel could play.
Small-group	discussion:	What	role	could	tenofovir	gel	play	in	the	
country?	
•	 Break participants into small groups mixed by discipline 
(policymakers, managers, providers)
•	 Ask groups to consider key questions from Module 3, such as:
 – Based on the HIV epidemic in the country, who do you think 
will most benefit from tenofovir gel?
 – Based on the country’s health-system capacity, which  
service settings afford good opportunities for implementing 
tenofovir gel?
 – What do you think will be the key barriers/obstacles for women 
who wish to access tenofovir gel?
 – What key challenges might providers face in providing 
tenofovir gel?
•	 Report back in plenary; facilitator synthesizes input to develop a goal 
statement that can guide tenofovir gel introduction. 
 –break–
SESSIOn	4	 Purpose: Participants examine specific program components




•	 Break into four groups, ensuring that each includes at least 
two participants with expertise in the discipline related to the 
specific program component being discussed:
 – Policy environment
 – User perspectives and demand creation
 – Service provision
 – Commodities, supply chain, and logistics
•	 Ask participants to review selected questions from Module 3 
related to these topics
•	 Report back in plenary; facilitator to synthesize key issues to 
address in introduction and implementation.
 –break–
SESSIOn	5	 Purpose: Discuss special issues and challenges related to
(1 hour) tenofovir gel. 
	 Expert	panel	discussion:	What	are	some	key	implications	and	
special	challenges	for	introducing	tenofovir	gel?
•	 A panel of in-country and international experts highlight 
selected issues from Module 3 about the impact tenofovir gel 
could have on HIV testing, potential resistance, and prevention 
options/method mix for HIV prevention, followed by a 
facilitated discussion and brainstorming with all participants 
to identify implications and issues.
SESSIOn	6  Purpose: Summarize key points from the discussions, identify
(0.5 hour) and prioritize next steps. 
 conclusions	and	next	steps:	The	way	forward
 –adjourn–
This sample details a facilitated discussion on program planning for tenofovir gel introduction. The agenda is based on Module 3: Program Planning 
Guide and outlines how a 1- or 1½-day workshop could be convened with country stakeholders to explore program implementation issues. Specific 
approaches to facilitation and the time allotted for each section will depend on the context, the size of the group, and attendees’ backgrounds.
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Appendix 3   
A Checklist for Service-Delivery Readiness
SEcTIOn	I:			
OPErATIOnS,	GUIDElInES,	fAcIlITy-rElATED	ElEmEnTS	
1. Written medical guidelines, protocols, and standards for ARV-based 
prevention exist and are available at the site.
2. Facilities have the necessary equipment and supplies to provide the 
product, including (to be modified depending on specific product):  
  · HIV test kits    
  · Pelvic models (at training facilities) 
  · Other
3. A range of HIV-prevention options are available and in stock  
at the site.
4. The facility has adequate space to ensure confidential HIV testing  
and counseling.
5. The facility has adequate space and conditions (temperature and 
humidity control, security, etc.) to store the product.
6. The facility has a system to forecast supply (and resupply)  
requirements, and uses it to prevent stock-outs. 
7. Client records are maintained and kept confidential. 
8. The facility has guidelines and clear linkages to facilitate integrated 


















Yes    No Comments
This checklist is intended for use by program managers and health providers  
to determine the readiness of service-delivery points to deliver ARV-based pre-
vention for women. The checklist is administered through direct observation 
by trained observers and/or researchers and can be used to:  1) identify key 
areas requiring attention prior to initiating ARV-based prevention services; or 
2) support the monitoring of related services once a product is introduced. The 
checklist promotes high-quality services and interactions between client and 
provider and is divided into two sections: 
•	SEcTIOn	I reviews overarching operations and facility-level components  
necessary for safe and effective product delivery. 
•	SEcTIOn	II reviews staffing/human resource and provider components es-
sential to deliver the product and to support provider–client interaction that 
ensures informed choice and decisionmaking concerning product adoption. 
The checklist should be updated and revised once service-delivery guidelines 






1. Providers have been trained to provide ARV-based 
prevention for women.
2. Providers have job aids that include clear, up-to-date 
information about the product. 
3. Providers follow protocols for infection prevention and safe 
disposal of medical waste. 
4. A system is in place to periodically assess staff competency 
and training needs.
5. Providers counsel clients about HIV testing and retesting, 
and on all available HIV-prevention options.
6. Providers ask clients about their reproductive intentions and, if 
desired, counsel and provide contraception or refer clients. 
7. Providers ensure client privacy and confidentiality.
8. Providers ensure that clients understand how the product 
works, including risks/benefits, side effects, effectiveness.
9. Providers give instructions to clients about how to use, care 
for, store, and dispose of product and related supplies. 
10. Providers are respectful of clients and tailor their interaction 
to clients’ needs, circumstances, and concerns. 
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